Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5152W HIGH $11.88
Volume
74.12 K
Value Traded
158.70 K
Short % Float
3.68%
-10.18%Week
-29.48%1 Month
-42.98%3 Month
-57.83%6 Month
-99.96%5 Year
-98.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
60.94 M
EPS (TTM)
-1.86
P/E Ratio
-
Ent. Value
-32.60 M
Total Shares
23.80 M
Float Shares
8.64 M
Insiders
63.69%
Institutions
19.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KLRS Catalyst Timeline
Dated clinical, regulatory and corporate events for Kalaris Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kalaris Therapeutics, Inc.
138Total events
7Upcoming
33Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Enrollment UpdateTH103Trial
Patient screening underway in Phase 1b/2 study of TH103
neovascular Age-related Macular Degenerationsource ↗
●Manufacturing MilestoneTH103CMC / Inspection
Latest drug product batch on track to be available to support upcoming dosing
neovascular Age-related Macular Degenerationsource ↗
◆Topline ReadoutTH103Clinical Data
Initial clinical data from Phase 1a SAD trial
neovascular age-related macular degeneration (nAMD)source ↗
▲Topline ReadoutTH103Clinical Data
Initial positive Phase 1a data for TH103 in treatment-naive nAMD
neovascular age-related macular degenerationsource ↗
●Oral PresentationTH103Presentation
Conference call and webcast to review initial Phase 1a data
neovascular age-related macular degenerationsource ↗
●Enrollment UpdateTH103Trial
Enrollment ongoing in Phase 1b/2 multi-ascending dose study
neovascular age-related macular degenerationsource ↗
▲Topline ReadoutTH103Clinical Data
Positive initial data reported from Phase 1a SAD study in nAMD
neovascular Age-related Macular Degeneration (nAMD)source ↗
◆Enrollment UpdateTH103Trial
Phase 1b/2 MAD trial currently enrolling
neovascular age-related macular degeneration (nAMD)source ↗
▲Partnership / LicenseTH103Corporate
CDMO agreement with KBI Biopharma for clinical supply manufacturing
◆Topline ReadoutTH103Clinical Data
Initial clinical data from Phase 1 trial of TH103 in nAMD expected
neovascular Age-related Macular Degeneration (nAMD)source ↗
●Enrollment UpdateTH103Trial
Continuing to enroll treatment-naive nAMD patients in Phase 1 trial of TH103
neovascular Age-related Macular Degeneration (nAMD)source ↗
◆Topline ReadoutTH103Clinical Data
Initial Phase 1 data expected
neovascular age-related macular degenerationsource ↗
▲First Patient DosedTH103Trial
First patient dosed in Phase 1b/2 MAD trial
neovascular Age-related Macular Degeneration (nAMD)source ↗
●Enrollment UpdateTH103Trial
Actively enrolling nAMD patients in Phase 1 trial of TH103
neovascular Age-related Macular Degeneration (nAMD)source ↗
◆Topline ReadoutTH103Clinical Data
Initial data from Part 1 of Phase 1 trial expected
neovascular Age-related Macular Degeneration (nAMD)source ↗
▲First Patient DosedTH103Trial
Phase 1 trial of TH103 commenced
neovascular age-related macular degenerationsource ↗
▲First Patient DosedTH103Trial
First patient dosed in Part 1 of Phase 1 trial of TH103
neovascular Age-related Macular Degeneration (nAMD)source ↗
▲First Patient DosedTH103Trial
First patient dosed in Phase 1 trial of TH103 for nAMD
neovascular Age-related Macular Degeneration (nAMD)source ↗
◆Topline ReadoutPosoleucelClinical Data
Topline data expected for Phase 3 multi-virus prevention trial
multi-virus prevention in allo-HCT patientssource ↗
◆Topline ReadoutPosoleucelClinical Data
Topline data from three Phase 3 registrational trials of posoleucel expected
three distinct indications in allo-HCT patientssource ↗
◆Oral PresentationALVR106Presentation
Data from Part A of ALVR106 trial accepted for presentation at scientific conference in Q1 2024
respiratory infections in transplant patientssource ↗
◆Topline ReadoutPosoleucelClinical Data
Data readout expected in 2024 for posoleucel Phase 3 prevention trial
prevention of multi-virus infections after allo-HCTsource ↗
▼Trial DiscontinuedPosoleucelTrial
Phase 3 prevention trial discontinued after DSMB futility analysis
prevention of clinically significant infections or diseases by multiple viruses after allo-HCTsource ↗
◆Enrollment CompletePosoleucelTrial
Enrollment completion anticipated by end of 2023 for posoleucel Phase 3 prevention trial
prevention of multi-virus infections after allo-HCTsource ↗
◆Enrollment UpdatePosoleucelTrial
Enrollment progressing in posoleucel pivotal Phase 3 multi-virus prevention study
multi-virus prevention in allo-HCT patientssource ↗
▲Enrollment CompleteALVR106Trial
ALVR106 completed enrollment in dose-escalation (Part A) portion of Phase 1b/2a trial
human metapneumovirus, influenza, parainfluenza, and respiratory syncytial virus in HCT and solid organ transplant patientssource ↗
▲Equity OfferingCorporate
Recent stock offering extends cash runway through Phase 3 data readouts and into 2025
▼Equity OfferingCorporate
Proposed underwritten public offering of $75 million of common stock
▲Oral PresentationPosoleucelPresentation
Positive Phase 2 data for posoleucel in BK viremia presented at ATC 2023 late-breaking session
BK viremia in kidney transplant recipientssource ↗
◆Enrollment UpdatePosoleucelTrial
Three Phase 3 registrational trials for posoleucel continue to enroll
prevention and treatment of viral infections in allo-HCT patientssource ↗
▲Full ResultsPosoleucelClinical Data
Final positive results from Phase 2 study of posoleucel for BK viremia reported
BK viremia in kidney transplant recipientssource ↗
▲Oral PresentationPosoleucelPresentation
Positive Phase 2 results for posoleucel in BK viremia to be presented at American Transplant Congress 2023
BK viremia in kidney transplant recipientssource ↗
◆Topline ReadoutPosoleucelClinical Data
Topline final data expected from Phase 2 BKV treatment study
BK viremia treatment in kidney transplant patientssource ↗
▲Full ResultsPosoleucelClinical Data
Positive final Phase 2 results for posoleucel in kidney transplant recipients with BK viremia announced
BK viremia in kidney transplant recipientssource ↗
Past FDA Catalysts and PDUFA Decisions
How KLRS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | TH103 | Phase 1a data readout | Phase 1a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 70%
Micro Cap(rank 461 of 658)
Percentile Rank
Kalaris Therapeutics, Inc. faces pipeline headwinds (30/100), with $48M risk-adjusted pipeline value, led by Posoleucel in Adenovirus Infection (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Posoleucel Cell therapyCompletedNCT04693637 | Adenovirus Infection | Phase 2 | COMPLETED | 26 | Jan 19, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every KLRS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TH103 | neovascular AMD | Phase 1a | 2025-12-17 | mean 10-letter gain in visual acuityRead More | Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Na ve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a siRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| AKKARAJU SRINIVASDirector, 10% Owner | Buy | 244,300 2,224,147 held | $4.83 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KLRS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 4.3 % (-41.1 %) | 52.43 M | 12.88 M | -0.52% ( -66.91 K) |
KLRS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KLRS ranks across every disease it competes in
Competitive Position is a premium feature
See how KLRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKLRS News
KLRSKalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Kalaris Therapeutics, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. The company, focused on developing treatments for retinal diseases, will have its management present at the event, highlighting its commitment to advancing its clinical-stage initiatives.
Read more →KLRSKalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kalaris has reported its financial results for Q2 2026, highlighting ongoing patient dosing in the Phase 1b/2 study of TH103. The company anticipates preliminary data in the first half of 2027 and is on track to initiate Phase 3 clinical trials by the end of 2027. As of June 30, 2026, Kalaris holds $93.5 million in cash and equivalents to support its operations.
Read more →KLRS▼ -8.7%on this news
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Kalaris has appointed Liisa Bayko as its new Chief Financial Officer, enhancing its leadership team. With over 20 years of experience in biotechnology, Bayko's addition is expected to support the company's growth. Kalaris is currently enrolling patients in its Phase 1b/2 study of TH103 for treatment-naïve nAMD patients.
Read more →KLRSKalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Therapeutics has reported encouraging results from the expanded cohorts of its Phase 1a SAD trial for TH103, showing positive outcomes in BCVA, OCT, and pharmacokinetics. The findings support the efficacy observed in earlier cohorts. The company continues to enroll participants in the Phase 1b/2 multiple-ascending dose trial, with preliminary data expected in the first half of 2027.
Read more →KLRSKalaris Appoints Laurie Keating to Board of Directors
Kalaris Therapeutics has appointed Laurie Keating to its Board of Directors. Keating is a highly experienced biotechnology executive, and her expertise is expected to support Kalaris in its upcoming growth phase. This strategic move reflects Kalaris's commitment to advancing its clinical-stage biopharmaceutical initiatives.
Read more →KLRSKalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Kalaris Therapeutics has announced an upcoming presentation of its Phase 1a clinical data at the American Society of Retina Specialists. The company is also actively enrolling participants in its Phase 1b/2 clinical trial. This highlights Kalaris's commitment to developing treatments for retinal diseases.
Read more →KLRSKalaris to Present at Clinical Trials at the Summit 2026
Kalaris Therapeutics will present Phase 1a clinical data for TH103 at the Clinical Trials at the Summit 2026. The data focuses on treatment-naïve patients with Neovascular Age-Related Macular Degeneration. The presentation will be led by Dr. Karl Csaky and is scheduled for June 13, 2026, in Las Vegas, NV.
Read more →KLRSKalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be
Kalaris Therapeutics, Inc. reported its financial results for the first quarter of 2026 and provided business updates. The company is currently screening patients in its Phase 1b/2 study for the drug TH103, aimed at treating neovascular Age-related Macular Degeneration, with preliminary data expected in the first half of 2027. Kalaris has $104.9 million in cash reserves, projected to fund operations through late 2027, while planned Phase 3 trials are slated for initiation by year-end 2027. However, a continued net loss and rising operational costs were noted in the financial report.
Read more →KLRSKalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics reported positive initial data from its Phase 1a trial for TH103, aimed at treating neovascular age-related macular degeneration (nAMD), and announced financial results for 2025. The company completed a $50 million private placement and expects its cash reserves will fund operations into the fourth quarter of 2027. While research and development expenses decreased, general administrative expenses rose sharply. Additionally, the net loss for the year was significantly lower than the previous year.
Read more →KLRSForward-Looking Statements & Disclaimer This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange A
Kalaris has provided insights into its forward-looking plans related to its lead drug candidate TH103, intended for retinal diseases. The company has outlined a timeline for clinical trials, however, it warns of various risks and uncertainties inherent to the development process. Additionally, Kalaris indicated it has sufficient cash resources to fund operations into late 2027, following a successful private placement. The drug TH103, which has shown initial promise, aims to address significant unmet medical needs in the market for retinal treatments.
Read more →KLRSKalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Kalaris Therapeutics will present Phase 1 clinical data for TH103 at the Macula Society Annual Meeting from February 25-28, 2026. The therapy, engineered for enhanced VEGF inhibition, targets treatment-naive patients with neovascular age-related macular degeneration. Key details include safety and efficacy outcomes from the study, presented by Dr. Dean Eliott.
Read more →KLRS▲ +20.3%on this news
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Kalaris Therapeutics has announced an oversubscribed private placement that will raise approximately $50 million. The offering, involving both new and existing institutional investors, is set to close soon and will be used to advance the clinical development of TH103 for neovascular AMD, alongside other corporate purposes. The securities will not be registered under the Securities Act, necessitating a registration rights agreement with the investors.
Read more →KLRS▲ +20.3%on this news
Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Na ve TH103 showed mean 10-letter gain in visual acuity and rapid, robust
Kalaris Therapeutics reported promising initial data from its Phase 1a study of TH103, indicating significant improvements in visual acuity and retinal anatomy in treatment-naive neovascular AMD patients. The treatment showed a mean gain of 10 letters in visual acuity at Month 1 and was generally well tolerated, prompting plans for further dose escalation. Moreover, a notable pharmacokinetic profile suggested enhanced intraocular retention, which may lead to extended treatment durability. Expected preliminary data from the ongoing Phase 1b/2 study is anticipated in the second half of 2026.
Read more →KLRSKalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics reported its financial results for Q3 2025, highlighting significant corporate milestones and progress in clinical trials. The Phase 1a Single Ascending Dose trial remains on schedule for initial data by year's end, while the Phase 1b/2 trial is currently enrolling participants. The company has substantial cash reserves of $77 million, projected to fund operations into 2027 even as R&D expenses reflect past obligations. Despite a notable net loss, the company is advancing its investigational treatment TH103 aimed at retinal diseases.
Read more →KLRS▼ -8.4%on this news
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics reported its financial results for Q2 2025, highlighting a net loss of $11.4 million, a significant increase from the previous year. The company continues to enroll patients in a Phase 1 trial for its new anti-VEGF agent, TH103, with initial data expected by Q4 2025. Kalaris currently holds $88.4 million in cash, which is projected to sustain operations through Q4 2026. The upward trend in R&D and administrative expenses indicates growing operational complexities as the company advances its clinical programs.
Read more →KLRSKalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Kalaris Therapeutics has reported its financial results for the first quarter of 2025, highlighting a cash position of $101 million due to the merger with AlloVir. The company is actively enrolling patients for its Phase 1 trial of TH103, an anti-VEGF therapy aimed at treating neovascular age-related macular degeneration. Despite a reported net loss of $10.2 million, the company expresses optimism about the clinical potential of TH103 and anticipates initial trial data in Q4 2025.
Read more →KLRSKalaris Announces Closing of Merger with AlloVir
Kalaris Therapeutics, Inc. has successfully completed its merger with AlloVir, enhancing its capabilities to develop TH103, an innovative anti-VEGF agent. TH103 aims to address treatment limitations for neovascular diseases of the retina, currently undergoing a Phase 1 trial with initial data projected for late 2025. The merger provides Kalaris with approximately $100 million in cash to sustain its operations well into 2026. As it transitions onto the Nasdaq Global Market under ticker KLRS, the company is poised for continued growth in the biopharmaceutical space.
Read more →KLRSKalaris and AlloVir Announce Stockholder Approval of Merger Combined company expected to trade on Nasdaq under KLRS after closing
Kalaris and AlloVir have announced that AlloVir stockholders approved the proposed merger during a special meeting. The merger, which is expected to close soon, will result in the new entity operating under the Kalaris name and trading on Nasdaq with the ticker KLRS. Kalaris, a clinical-stage biopharmaceutical company, is focused on developing treatments for retinal diseases, notably its investigational therapy TH103. However, the completion of the merger faces various market and operational uncertainties.
Read more →KLRSAlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and
AlloVir Inc. has entered into a definitive merger agreement with Kalaris Therapeutics to create a combined entity focused on retinal diseases. The merger will involve AlloVir acquiring Kalaris, leading to a company that will operate under the Kalaris name and trade under the ticker KLRS. The new entity aims to accelerate the clinical development of TH103, a novel anti-VEGF therapy for conditions such as neovascular age-related macular degeneration. With an anticipated cash balance of approximately $100 million post-merger, the combination is projected to fund operations into Q4 2026. Initial clinical data for TH103 is expected in Q3 2025.
Read more →KLRSAlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
AlloVir and Kalaris Therapeutics have announced a merger agreement aimed at forming a new company dedicated to addressing diseases of the retina. This strategic move is expected to consolidate their efforts in research and development, potentially leading to innovative solutions in the field. The merger reflects a commitment to advancing treatment options for retinal conditions.
Read more →About Kalaris Therapeutics, Inc.
Headquarters400 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922
BIOPHARMAWATCH ELITE PLUS
Trade the next KLRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime